Recombinant Human Uncharacterized protein C3orf45 (C3orf45)

What is recombinant human IL-34 and what is its biological significance?

Interleukin 34 (IL-34) is a secreted homodimer consisting of 39 kDa monomers that belongs to no known cytokine family. Human IL-34 is synthesized as a 242 amino acid precursor with a 20 amino acid signal sequence and a 222 amino acid mature chain. The protein contains one potential site of N-linked glycosylation and shares 71% identity with mouse IL-34 at the amino acid level. IL-34 is widely expressed in various tissues including heart, brain, liver, kidney, spleen, thymus, testes, ovary, small intestine, prostate, and colon, with highest abundance in the spleen. The protein signals through colony-stimulating factor 1 receptor (CSF-1R) and stimulates monocyte proliferation .

What formulation options are available for recombinant human IL-34?

Recombinant human IL-34 is available in two primary formulations:

• With carrier protein (5265-IL): Lyophilized from a 0.2 μm filtered solution in PBS and NaCl with BSA as a carrier protein. This formulation enhances protein stability, increases shelf-life, and allows storage at more dilute concentrations .

• Carrier-free (5265-IL/CF): Lyophilized from a 0.2 μm filtered solution in PBS and NaCl without BSA. This formulation is recommended for applications where BSA might interfere with experimental outcomes .

What are the recommended reconstitution protocols for recombinant IL-34?

For optimal results, follow these reconstitution protocols:

• Standard formulation (5265-IL): Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin .

• Carrier-free formulation (5265-IL/CF): Reconstitute at 100 μg/mL in sterile PBS .

For both formulations, it's recommended to use a manual defrost freezer and avoid repeated freeze-thaw cycles to maintain protein integrity and activity .

How should researchers design experiments to evaluate IL-34 biological activity?

When designing experiments to evaluate IL-34 biological activity, researchers should consider:

• Dose determination: The effective dose (ED50) for IL-34-induced proliferation in human peripheral blood monocytes is 0.75-3.75 ng/mL. Design dose-response experiments within and beyond this range to establish the optimal concentration for your specific cell system .

• Appropriate controls: Include both positive controls (known CSF-1R activators) and negative controls (vehicle only) to validate IL-34 activity.

• Experimental approach selection: Consider implementing randomized controlled trial (RCT) designs when evaluating IL-34 effects, particularly when comparing multiple treatment conditions. Implementation-focused RCTs differ from traditional efficacy- or effectiveness-oriented RCTs on key parameters .

What experimental models are suitable for studying IL-34 functions?

Based on the literature, several experimental models have been successfully used to study IL-34 functions:

• Human peripheral blood monocytes: Used to study proliferation responses and ERK1/2 phosphorylation .

• Human bone marrow cultures: Employed to evaluate the formation of colony-forming unit-macrophage (CFU-M) .

• Human iPSC-derived microglia-like cells: Used to study neuroinflammatory processes and microglial functions in disease contexts .

• Human monocyte-derived macrophages: Applied to investigate IL-34-induced phenotypic changes and cytokine production .

When selecting an experimental model, researchers should consider the specific biological question being addressed and choose the most relevant cell type or system .

How can quasi-experimental designs be applied to IL-34 research?

For research questions where randomization is not feasible, quasi-experimental designs offer valuable alternatives:

• Pre-post designs with non-equivalent control groups: Useful when studying IL-34 effects in naturally occurring populations or when randomization is ethically problematic. This approach compares outcomes before and after intervention while accounting for baseline differences between groups .

• Interrupted time series (ITS): Appropriate for evaluating temporal effects of IL-34 treatments or interventions. This method involves collecting multiple observations before and after introducing IL-34, allowing researchers to distinguish between immediate effects and trends over time .

• Stepped wedge designs: Beneficial when all participants must eventually receive IL-34 treatment but implementation needs to be staggered. This approach introduces the intervention to different groups at different timepoints, allowing for both between-group and within-group comparisons .

What analytical approaches are recommended for IL-34 signaling pathway studies?

When investigating IL-34 signaling pathways, consider these analytical approaches:

• Phosphorylation analysis: IL-34 stimulates phosphorylation of extracellular signal-regulated kinase-1 and -2 (ERK1/2) in human monocytes, similar to CSF-1. Quantitative analysis of phosphorylation events can help elucidate downstream signaling mechanisms .

• JAK/STAT pathway analysis: Evidence suggests IL-34 may signal through JAK3/STAT6 pathways in certain contexts, warranting investigation of these signaling components .

• Comparative analysis with CSF-1: As both IL-34 and CSF-1 bind to CSF-1R, comparative studies of their signaling pathways can reveal unique and shared mechanisms of action .

How is IL-34 implicated in neurological disease research?

IL-34 has been studied in various neurological disease contexts:

• Alzheimer's disease: Research indicates reduced levels of SH3RF3 may protect against Alzheimer's disease by lowering microglial pro-inflammatory responses via modulation of JNK and NFkB signaling, with IL-34 playing a role in this process .

• Parkinson's disease: Studies have examined how α-synuclein assemblies combined with chronic-type inflammatory cues promote neurotoxic microglial phenotypes, with IL-34 being relevant to microglial activation states .

• Nasu-Hakola disease: Research has investigated dynamic microglial dysfunction in this condition using IL-34-induced microglia-like cells derived from human monocytes .

What methodological considerations are important when studying IL-34 in infection and immunity?

When investigating IL-34 in infection and immunity contexts:

• Viral infection models: Studies have shown IL-34 can inhibit hepatitis B virus replication in vitro and in vivo, suggesting specific methodological approaches for viral infection research .

• T cell differentiation: IL-34 and M-CSF-induced macrophages can switch memory T cells into Th17 cells via membrane IL-1α, requiring careful experimental design to track cellular phenotypic changes .

• Species-specific considerations: When designing experiments, consider species-specific differences in IL-34 activity. Human IL-34 shares only 71% amino acid identity with mouse IL-34, and studies have shown species specificity in stimulation by IL-34 across different species including feline models .

What statistical approaches are recommended for analyzing IL-34 experimental data?

When analyzing experimental data involving IL-34:

• Define your methodological approach: Clearly articulate whether your research is quantitative, qualitative, or mixed-methods. This fundamental decision will guide your entire analytical framework .

• Control for research biases: Implement appropriate controls and blinding procedures to minimize confirmation bias, especially when evaluating subjective outcomes in IL-34 experiments .

• Justify analytical choices: Document why particular analytical methods were selected over alternatives, especially when dealing with complex datasets from IL-34 signaling studies .

• Consider implementation science frameworks: For translational IL-34 research, implementation science approaches can help bridge the gap between basic research findings and clinical applications .

How should researchers address contradictory findings in IL-34 studies?

When confronting contradictory findings in IL-34 research:

• Evaluate methodological differences: Carefully examine differences in experimental design, cell types, protein formulations, and analytical approaches that might explain divergent results .

• Consider contextual factors: IL-34 functions may vary depending on cell type, tissue context, and disease state. What appears contradictory might reflect biological complexity rather than experimental error .

• Implement replication studies: Design studies that specifically aim to replicate contradictory findings while controlling for key variables that might explain differences .

• Meta-analytical approaches: When multiple studies show contradictory results, consider formal meta-analytical techniques to synthesize findings across studies and identify patterns that explain apparent contradictions .

What are the key ethical considerations for IL-34 research in human models?

Researchers working with IL-34 in human models should consider:

• Source material ethics: When using human primary cells for IL-34 studies, ensure appropriate informed consent and ethical approval procedures are followed .

• Translational implications: As IL-34 research may have implications for diseases like Alzheimer's, Parkinson's, and rheumatoid arthritis, consider the ethical implications of findings and how they are communicated .

• Study design ethics: When implementing experimental or quasi-experimental designs, carefully weigh the ethical implications of control group selection and treatment allocation .

What are the best practices for long-term storage and stability of recombinant IL-34?

To maintain IL-34 stability and activity:

• Storage conditions: Store reconstituted IL-34 at the recommended temperature. Use a manual defrost freezer and avoid repeated freeze-thaw cycles which can degrade protein activity .

• Aliquoting strategy: Prepare single-use aliquots immediately after reconstitution to minimize freeze-thaw cycles .

• Carrier protein considerations: For long-term storage of dilute solutions, consider using the formulation with carrier protein (BSA) as it enhances stability and increases shelf-life .

• Quality control: Periodically verify protein activity through functional assays, such as monocyte proliferation tests, where the ED50 should be 0.75-3.75 ng/mL .